Publications

BibTex format

@article{De:2019:10.3389/fpsyt.2018.00708,
author = {De, Beaurepaire R and Sinclair, JMA and Heydtmann, M and Addolorato, G and Aubin, H-J and Beraha, EM and Caputo, F and Chick, JD and de, la Selle P and Franchitto, N and Garbutt, JC and Haber, PS and Jaury, P and Lingford-Hughes, AR and Morley, KC and Muller, CA and Owens, L and Pastor, A and Paterson, LM and Pelissier, F and Rolland, B and Stafford, A and Thompson, A and van, den Brink W and Leggio, L and Agabio, R},
doi = {10.3389/fpsyt.2018.00708},
journal = {Frontiers in Psychiatry},
title = {The use of Baclofen as a treatment for alcohol use disorder: A clinical practice perspective},
url = {http://dx.doi.org/10.3389/fpsyt.2018.00708},
volume = {9},
year = {2019}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Alcohol use disorder (AUD) is a brain disorder associated with high rates of mortality and morbidity worldwide. Baclofen, a selective gamma-aminobutyric acid-B (GABA-B) receptor agonist, has emerged as a promising drug for AUD. The use of this drug remains controversial, in part due to uncertainty regarding dosing and efficacy, alongside concerns about safety. To date there have been 15 randomized controlled trials (RCTs) investigating the use of baclofen in AUD; three using doses over 100 mg/day. Two additional RCTs have been completed but have not yet been published. Most trials used fixed dosing of 30–80 mg/day. The other approach involved titration until the desired clinical effect was achieved, or unwanted effects emerged. The maintenance dose varies widely from 30 to more than 300 mg/day. Baclofen may be particularly advantageous in those with liver disease, due to its limited hepatic metabolism and safe profile in this population. Patients should be informed that the use of baclofen for AUD is as an “off-label” prescription, that no optimal fixed dose has been established, and that existing clinical evidence on efficacy is inconsistent. Baclofen therapy requires careful medical monitoring due to safety considerations, particularly at higher doses and in those with comorbid physical and/or psychiatric conditions. Baclofen is mostly used in some European countries and Australia, and in particular, for patients who have not benefitted from the currently used and approved medications for AUD.
AU  - De,Beaurepaire R
AU  - Sinclair,JMA
AU  - Heydtmann,M
AU  - Addolorato,G
AU  - Aubin,H-J
AU  - Beraha,EM
AU  - Caputo,F
AU  - Chick,JD
AU  - de,la Selle P
AU  - Franchitto,N
AU  - Garbutt,JC
AU  - Haber,PS
AU  - Jaury,P
AU  - Lingford-Hughes,AR
AU  - Morley,KC
AU  - Muller,CA
AU  - Owens,L
AU  - Pastor,A
AU  - Paterson,LM
AU  - Pelissier,F
AU  - Rolland,B
AU  - Stafford,A
AU  - Thompson,A
AU  - van,den Brink W
AU  - Leggio,L
AU  - Agabio,R
DO  - 10.3389/fpsyt.2018.00708
PY  - 2019///
SN  - 1664-0640
TI  - The use of Baclofen as a treatment for alcohol use disorder: A clinical practice perspective
T2  - Frontiers in Psychiatry
UR  - http://dx.doi.org/10.3389/fpsyt.2018.00708
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000454890300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/67451
VL  - 9
ER  -

Download

DrLouisePaterson

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)